Navigation Links
GENova issues clarifying press release
Date:9/12/2009

NEW YORK, Sept. 12 /PRNewswire-FirstCall/ - GENova Biotherapeutics Inc. ("GENova") clarified today information disseminated in previous press releases regarding the patents currently in GENova's IP portfolio.

GENova owns the rights to a range of drug targets and has filed patent application for all of them. The patents have not yet been approved and are therefore considered 'patents-pending'. It has been brought to GENova's attention that previous releases were not entirely clear on this issue and may have been misconstrued by some investors. Any statements made prior to this announcement which stated or implied that patents have been granted are incorrect and should not be relied upon in making investment decisions.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these drug product candidates to Big Pharmaceutical and Biotechnology companies.Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owne
'/>"/>

SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. GENova names Aaron Whiteman as CEO
2. GENova names Dr. John Savin as Vice President
3. Genova files patent for new prostate cancer treatment
4. GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
5. GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
6. GENova appoints Director of Asian business development
7. GENova files patent for new breast cancer treatment
8. GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees
9. College Mental Health Expert and Sister of Student Who Died By Suicide Available to Discuss College Mental Health Issues
10. PowerBar Issues Open Call for 2008-2009 PowerBar Team Elite(TM) Athlete Sponsorship Program
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Ask not what your racquet can do for you but ... racquet. With the launch of their new digital campaign, HEAD ... tricks and unique skill to HEAD Pro Players and consumers ... artist playfully demonstrates how to gain more control over the ... also challenges tennis enthusiasts everywhere to join the show. , ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 The MIT ... case study featuring Healthcare IQ. Members of the MIT ... senior management team to develop the case study about ... healthcare analytics. , The case study, ‘Healthcare IQ: Competing ... IQ from its beginning as a hospital financial software ...
(Date:5/28/2015)... First Choice Emergency Room , the ... United States, announced that it is expanding in the ... Ranch facility. , “I am pleased to announce ... quality emergency medical care to Denver residents with our ... James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:5/28/2015)... Orem, UT—Dymicron, Inc., (dymicron.com) confirmed the successful ... Triadyme-C cervical total disc replacement device. The two surgeries ... at the American Institute of Minimally Invasive Surgery (AIMIS) ... to the implantation of the Dymicron devices,” said Dr. ... Chief of Neurosurgery for the University Medical Center, Las ...
(Date:5/28/2015)... 2015 Career Step, an online provider ... announce that Career Step Executive Vice President Mike Hodgson ... webinar presented by ICD10monitor in conjunction with Kimberly J. ... Hodgson and Ms. Carr will be discussing the importance ... transition. , “We have worked closely with HRS on ...
Breaking Medicine News(10 mins):Health News:Tennis Artist Baffles Novak Djokovic - HEAD Launches Trick Shot Campaign “Frame & Play” 2Health News:Healthcare IQ, the “Switzerland” of Healthcare Spend Analytics, Featured in MIT Case Study 2Health News:Healthcare IQ, the “Switzerland” of Healthcare Spend Analytics, Featured in MIT Case Study 3Health News:First Choice Emergency Room to Open New Facility in Denver, Colorado 2Health News:Dymicron, Inc., Announces the First Human Implantation of their Triadyme-CTM Cervical Total Disc Replacement Device in Cyprus 2Health News:Career Step and HRS Hosting June 4 ICD10monitor Webinar on the Importance of Auditing and Physician Training for ICD-10 Success 2Health News:Career Step and HRS Hosting June 4 ICD10monitor Webinar on the Importance of Auditing and Physician Training for ICD-10 Success 3
... in fighting tooth decay has been developed by BASF, a German ... year. The company claims its// product can reduce the amount ... product was developed in collaboration with another German company OrganoBalance. ... the Streptococcus mutans (bacteria involved in tooth decay) from adhering to ...
... on junk foods and soft drinks in hospitals, schools ... of diabetes and obesity. Australia// has the world's ... with type-2 diabetes. ,In an article published ... Director of the International Diabetes Institute in Melbourne, and ...
... annual back-to-school survey on teens' attitudes that covers an overall ... practices, one// third of the American teenagers have attended parties ... were at home. ,It doesn’t imply that parents ... their homes. In fact, only 12 % of parents look ...
... According to some Swiss scientists, a new kind of breast ... is reliable.// ,Already, doctors have been using core ... ,This new test involves the study of ... more aggressive cancers that need intensive treatment. But the test ...
... fields, including math and science fields, due to their ... study. ,Researchers at RTI International, University of ... 1990 study looked at 137 female high school seniors ... later, the study found that 83 percent of those ...
... Family Health Survey for Punjab is bittersweet. While Punjab ... to retain the fertility// level at two children per woman, ... rates. Nearly 38% women and 30% men are obese, ... by CRRID in Punjab, studied nearly 3000 households. Gopal Krishan, ...
Cached Medicine News:Health News:Parents ignorant about kids' immoral practices 2Health News:Novel test for diagnosis of breast cancer 2
(Date:5/28/2015)... May 28, 2015  The recent flurry of ... and employer groups scrambling to identify a pharmacy ... managed care plan, retail pharmacy chain, or other ... billion purchase of Catamaran, Rite Aid,s $2 billion ... purchase Omni-Care for $10 billion are just the ...
(Date:5/28/2015)... May 28, 2015   Sanovas, Inc., a rapidly ... the Top 50 Start-Up Companies in the World at the Silicon ... Logo - http://photos.prnewswire.com/prnh/20150528/219097LOGO ... segment experts with direct domain experience screened 2,716 companies from ... Property, Business Model, and Team. This select list was further ...
(Date:5/28/2015)... 28, 2015  Array BioPharma Inc. (NASDAQ: ARRY ... (licensed to AstraZeneca) at the 2015 American Society of ... May 29 – June 2, 2015 in ... advancing in a total of 6 pivotal trials, with ... (binimetinib monotherapy in NRAS mutant melanoma patients) and SUMIT ...
Breaking Medicine Technology:Citizens Rx Addresses Recent PBM Consolidation and Rising Pharmacy Costs 2Citizens Rx Addresses Recent PBM Consolidation and Rising Pharmacy Costs 3Sanovas Awarded Global "Top-50" Start-Up Company 2Sanovas Awarded Global "Top-50" Start-Up Company 3Array BioPharma Announces Clinical Data Presentations At The 2015 ASCO Annual Meeting 2Array BioPharma Announces Clinical Data Presentations At The 2015 ASCO Annual Meeting 3
... 1, 2011 Serina Therapeutics, Inc. President and CEO Randall ... a $9.5 million financing round to advance its lead oncology ... early 2012. "We are pleased to report to ... round that was launched in late 2010. This is a ...
... 2011 Endo Pharmaceuticals (Nasdaq: ENDP ) today ... officer will present a corporate overview at the Goldman Sachs ... p.m. PT.  The conference will be held at the Terranea ... webcast and audio archive of the presentation will be available ...
Cached Medicine Technology:Serina Therapeutics, Inc. Closes $9.5 Million Financing Round 2
Coronet Vacuum Trephine - All metal, ergonomic design and ultra sharp blade with cross hairs....
Corneal Marker - 8 blades, 2 sizes available: 7.0mm, 8.0mm. 1 piece per box...
... maintains almost all its mechanical strength throughout ... in 915 months. Blunt thread design assists ... to maximize surgeons options. Driver design ... to help prevent the screw from breaking ...
... a robotic sample feeder that interfaces with the ... robotic arm and the SMS software. Continuous sample ... compatibility with clinical chemistry system racks are just ... a practical and affordable solution for improving productivity. ...
Medicine Products: